Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P00414

UPID:
COX3_HUMAN

ALTERNATIVE NAMES:
Cytochrome c oxidase polypeptide III

ALTERNATIVE UPACC:
P00414; Q14Y83

BACKGROUND:
As a component of cytochrome c oxidase, Cytochrome c oxidase subunit 3 is integral to the mitochondrial electron transport chain, essential for the catalytic reduction of oxygen to water. This process is vital for ATP production, highlighting the protein's role in cellular metabolism and energy homeostasis. The enzyme's mechanism involves the transfer of electrons and protons, illustrating the sophisticated nature of mitochondrial function.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in critical mitochondrial diseases such as Leber hereditary optic neuropathy and Mitochondrial complex IV deficiency, Cytochrome c oxidase subunit 3 represents a significant target for drug discovery. The protein's role in these diseases offers a unique opportunity for the development of targeted therapies, potentially transforming the treatment landscape for patients with mitochondrial disorders. Understanding the role of Cytochrome c oxidase subunit 3 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.